Recro Pharma Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Recro Pharma (REPH) Tops Q1 EPS by 96c, Revenues Beat; Offers FY19 Revenue Guidance Above Consensus
May 10, 2019 7:09 AM EDTRecro Pharma (NASDAQ: REPH) reported Q1 EPS of ($0.10), $0.96 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $25.07 million versus the consensus estimate of $20.51 million.
Our CDMO business is off to a strong start this year, generating $25.1 million in first quarter revenues, a 28% increase from the prior year first quarter, said Gerri Henwood, President and Chief Executive Officer of Recro Pharma. Growth of the Gainesville CDMO continues to accelerate as a result of strong demand... More
